Jialiang Brain Science

Genlight MedTech, also referred to as Jialiang Brain Science, is a medical device company established in 2020 and headquartered in Hangzhou, China. The firm focuses on developing and industrializing technologies for neurosurgery and brain science. Its research and development are concentrated on creating solutions for neurological conditions such as drug-refractory epilepsy, brain tumors, Parkinson's disease, and depression.

The company's product portfolio is built on several advanced technology platforms, including brain-computer interfaces, medical lasers, and brain-computer chips. Key products include LaserRO, an MRI-guided laser ablation (LITT) minimally invasive surgical system, and BCmod, a closed-loop neuromodulation technology platform for central nervous system diseases. They also provide neurosurgical robots and scientific research services based on neurocognition. Two of its products have received breakthrough device designation from the NMPA, China's medical products regulator.

Since its founding, Genlight has achieved several milestones, including securing Pre-Series A and Series B+ funding, the acquisition of Hangzhou Nuowei Medical in 2021, and being named a "Hangzhou Future Unicorn" in 2023. The company actively collaborates with academic institutions, such as establishing a joint research and development center with Zhejiang University of Technology. As of 2023, Genlight employed approximately 170 people and held over 160 patents.

Keywords: neurosurgery, medical devices, brain science, neurological disorders, brain-computer interface, neuromodulation, laser ablation, LITT, epilepsy treatment, Parkinson's disease, brain tumors, neurotechnology, medical lasers, Hangzhou, Genlight MedTech, Jialiang Brain Science, LaserRO, BCmod, closed-loop neurostimulation, SEEG electrode, NMPA, surgical robotics, neurocognition.